-Reutuers
Baird Maintains Outperform on Taysha Gene Therapies, Lowers Price Target to $21
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and lowers the price target from $26 to $21.
Related Posts
Appian Drives Productivity Revolution With Generative AI Strategy And Expanded AI Roadmap
Process automation leader delivers practical value for professional low-code developers.MCLEAN, Va, June 12, 2023 /PRNewswire/ -- Appian (NASDAQ:APPN) today announced key elements of its expanded strategy and roadmap for
Price Over Earnings Overview: Apple
In the current session, the stock is trading at $185.78, after a 0.99% increase. Over the past month,…
Expensify And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by more than 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.